Quality of life in primary aldosteronism, medical vs surgical treatment: a systematic review and meta-analysis.
Merel Wever, Christian Basile, Emanuele Bobbio et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined the impact of treatment on quality of life (QoL) in patients with primary aldosteronism (PA) undergoing either unilateral adrenalectomy (ADX) or medical treatment with mineralocorticoid receptor antagonists (MRA). The analysis included 15 studies, revealing that while QoL improved in both groups, there was no statistically significant difference at 6 months post-treatment.
Key findings
- QoL improved in both ADX and MRA groups at 6 months.
- Most studies indicated greater and faster QoL improvement after ADX compared to MRA.
- Patients treated with MRA were older and often received low doses.
Why it matters
Understanding the effects of different treatment modalities on QoL is crucial for clinicians managing primary aldosteronism, as it informs treatment decisions and patient expectations regarding recovery and well-being.
What to keep in mind
The limited number of patients and short follow-up duration were noted as important limitations.